Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)

Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m(2) every 4 weeks in patients with soft tissue sarcomas. Methods. DXR was given IV bolus and IFOS by continuous infusion at 2 g/m(2)/day. Initial IFOS dose (12 g/m(2)) was a...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Pousa, A., Martín, J., Montalar, J., de las Peñas, R., García del Muro, J., Cruz, J., Maurel, J., Escudero, P., Casado, A., Buesa, J. M., the Spanish Group for Research on Sarcomas (GEIS)
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698138/
https://www.ncbi.nlm.nih.gov/pubmed/17251655
http://dx.doi.org/10.1155/SRCM/2006/26986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698138/
https://www.ncbi.nlm.nih.gov/pubmed/17251655
http://dx.doi.org/10.1155/SRCM/2006/26986

Ejemplares similares